Restenosis patterns after bioresorbable vascular scaffold implantation: Angiographic substudy of the <scp>GHOST</scp>‐<scp>EU</scp> registry

Baquet, Moritz; Nef, Holger; Gori, T; Latib, Azeem; Capodanno, Davide; Mario, Carlo Di; Sabaté, Manel; Colombo, Antonio; Tamburino, Corrado; Mehilli, Julinda

doi:10.1002/ccd.27350

Cited by 6 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is also in line with findings of Jabbour et al who observed a higher amount of TLR within BVS segments compared to DES segments . As confirmed by prior investigations, instent restenosis of BVS and DES showed predominantly focal pattern and were treated by DEB or DES …”

Section: Discussionsupporting

confidence: 91%

Hybrid‐stenting with metallic and bioresorbable drug‐eluting stents 2‐year clinical outcomes in KUM ABSORB registry

Baquet

Grundmann

Schmidt

et al. 2018

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Hybrid‐stenting with metallic and bioresorbable drug‐eluting stents 2‐year clinical outcomes in KUM ABSORB registry

Baquet

Grundmann

Schmidt

et al. 2018

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

show abstract

“…Correspondingly, the material needs to be both corrosion and fatigue resistant as well as capable of negligible induction of stent restenosis in the long term [12] . In the past few years, BVS technology has been applied in the coronary arterial system for providing vascular support and potential anti-proliferative drug delivery [65] .…”

Section: Bioresorbable Vascular Scaffoldmentioning

confidence: 99%

Current Status and Prospect of Stent Placement for May-Thurner Syndrome

Liu

Lü

et al. 2021

CURR MED SCI

View full text Add to dashboard Cite

Stent implantation has been proven to be safe and has become the first-line intervention for May-Thurner syndrome (MTS), with satisfactory mid-term patency rates and clinical outcomes. Recent research has demonstrated that catheter-directed thrombolysis is the preferred strategy when MTS is combined with deep vein thrombosis after self-expanding stent placement. However, the stent used for the venous system was developed based on the experience obtained in the treatment of arterial disease. Consequently, relatively common corresponding complications may come along later, which include stent displacement, deformation, and obstruction. Different measures such as adopting a stent with a larger diameter, improving stent flexibility, and increasing stent strength have been employed in order to prevent these complications. The ideal venous stent is presently being evaluated and will be introduced in detail in this review.

show abstract

“…This discrepancy could be explained by the presence of smaller vessel diameter in the distal subsegments leading to scaffold oversizing, and potentially less aggressive post‐dilatation due to the challenge in visualizing the tantalum markers. OCT assessment of magnesium BRS has shown an increase of lumen volume loss when expansion index is >1, and previous data on Absorb BVS have correlated implantation in small vessel diameter with a higher rate of in‐device restenosis, eccentricity, and asymmetry . Performing pre‐procedural intracoronary imaging for vessel sizing and lesion characterization might help to further improve lesion/device selection .…”

Section: Discussionmentioning

confidence: 94%

Serial invasive imaging follow‐up of the first clinical experience with the Magmaris magnesium bioresorbable scaffold

Forero

Zandvoort

Masdjedi

et al. 2019

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objectives: To assess the performance of the commercially available Magmaris sirolimuseluting bioresorbable scaffold (BRS) with invasive imaging at different time points.Background: Coronary BRS with a magnesium backbone have been recently studied as an alternative to polymeric scaffolds, providing enhanced vessel support and a faster resorption rate. We aimed to assess the performance of the commercially available Magmaris sirolimus-eluting BRS at different time points.Methods: A prospective, single-center, nonrandomized study was performed at the Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands. Six patients with stable de novo coronary artery lesions underwent single-vessel revascularization with the Magmaris sirolimus-eluting BRS. Invasive follow-up including intravascular imaging using optical coherence tomography (OCT) was performed at different time points.Results: At a median of 8 months (range 4-12 months) target lesion failure occurred in one patient. Angiography revealed a late lumen loss of 0.59 ± 0.39 mm, a percentage diameter stenosis of 39.65 ± 15.81%, and a binary restenosis rate of 33.3%. OCT showed a significant reduction in both minimal lumen area (MLA) and scaffold area at the site of the MLA by 43.44 ± 28.62 and 38.20 ± 25.74%, respectively. A fast and heterogeneous scaffold degradation process was found with a significant reduction of patent struts at 4-5 months.Conclusions: Our findings show that the latest iteration of magnesium BRS suffers from premature dismantling, resulting in a higher than expected decrease in MLA. K E Y W O R D S bioresorbable scaffolds, constrictive remodeling, Magmaris sirolimus-eluting bioresorbable scaffold, scaffold bioresorption, scaffold collapse, scaffold recoil Abbreviations: AMS, absorbable magnesium scaffolds; BRS, bioresorbable scaffold; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; DS, diameter stenosis; LA, lumen area; LLL, late lumen loss; MLA, minimal lumen area; MSA, minimal scaffold area; NC, noncompliant; OCT, optical coherence tomography; post-PCI, post-percutaneous coronary intervention; pre-PCI, prepercutaneous coronary intervention; QCA, quantitative coronary analysis; RVD, reference vessel diameter; SA, scaffold area; SE-MEA, scaffold expansion according to manufacturer's expected area; SE-RVA, scaffold expansion according to reference vessel area.

show abstract

Restenosis patterns after bioresorbable vascular scaffold implantation: Angiographic substudy of the GHOST‐EU registry

Abstract: The IBR morphology is mostly focal involving particularly the BVS margins suggesting association with procedural aspects in this early experience with BVS. Treatment of small vessels is the strongest predictor of higher IBR risk.

Cited by 6 publications

References 39 publications

Hybrid‐stenting with metallic and bioresorbable drug‐eluting stents 2‐year clinical outcomes in KUM ABSORB registry

Hybrid‐stenting with metallic and bioresorbable drug‐eluting stents 2‐year clinical outcomes in KUM ABSORB registry

Current Status and Prospect of Stent Placement for May-Thurner Syndrome

Serial invasive imaging follow‐up of the first clinical experience with the Magmaris magnesium bioresorbable scaffold

Contact Info

Product

Resources

About